BRIUMVI's Success Powers TG Therapeutics to Higher Revenue Targets and Enhanced Shareholder Returns
Third Quarter Highlights: Revenue Momentum Accelerates, Guidance Raised Again
TG Therapeutics (NASDAQ:TGTX) reported robust third quarter 2025 results, highlighting the surging momentum of its lead therapy, BRIUMVI. U.S. net revenue from BRIUMVI reached $152.9 million for the quarter, representing an 84% jump over Q3 2024 and a 10% increase from the prior quarter. With broadening market adoption, the company now targets $585 million in U.S. BRIUMVI net revenue for 2025—up from previous guidance of $570-575 million—and total global revenue of approximately $600 million.
This confidence in top-line growth is further reflected in management’s decision to complete a $100 million share repurchase and authorize an additional $100 million program, a rare move among small and mid-cap biotech firms. As of September 30, TGTX’s cash and investment securities position stood at $178.3 million, with ongoing product sales expected to cover operational needs based on current plans.
Key Financials at a Glance: Profitability Leaps on One-Time Tax Benefit
| Financial Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Product Revenue, Net | $159.32M | $83.30M | $417.82M | $206.38M |
| Total Revenue | $161.71M | $83.88M | $423.71M | $220.82M |
| Operating Profit | $29.37M | $12.43M | $72.83M | $11.98M |
| Net Income | $390.90M* | $3.88M | $424.14M* | $0.05M |
| Cash, Cash Equivalents & Investments (as of 9/30/25) | $178.32M | |||
*Q3 net income includes a non-recurring $365M income tax benefit due to release of a deferred tax asset valuation allowance.
Clinical Progress and Commercial Expansion: Fueling Long-Term Value
Beyond financials, TGTX is executing on its R&D pipeline. Key developments include:
- Initiated enrollment for a Phase 3 trial of subcutaneous ublituximab (an alternative BRIUMVI delivery format).
- Completed enrollment for a Phase 3 trial evaluating a simplified intravenous BRIUMVI dosing regimen, aimed at improving patient convenience and potentially strengthening the label.
- Expanded global BRIUMVI commercialization through a partnership with Neuraxpharm, with new approvals in Europe, UK, Switzerland, Australia, Kuwait, and UAE.
- Long-term data presented at ECTRIMS showed that 89.9% of patients with relapsing multiple sclerosis (RMS) were free from 24-week confirmed disability progression after six years on BRIUMVI, reinforcing its safety and durability.
Shareholder Focus: Second $100 Million Buyback Announced
TGTX’s Board completed the previously announced $100 million buyback, acquiring about 3.5 million shares at an average price of $28.55. Now, with a new $100 million authorization, the company signals confidence in its trajectory and intent to return capital to shareholders, even while reinvesting in growth initiatives.
Financial Health and Risk Outlook
Cash, product sales, and cost management put TGTX in a sound position, with cash and equivalents at $178.3 million. Guidance is clear: current reserves plus future BRIUMVI revenues should fund ongoing operations, research, and clinical trials. However, as with all biotech investments, future progress depends on sustained BRIUMVI market performance, successful execution of clinical milestones, and continued payor and physician support.
Key Takeaways for Investors
- Guidance Lifted: Strong U.S. BRIUMVI demand drove the second upward guidance revision in 2025.
- Shareholder Return: A second $100 million buyback signals conviction from leadership.
- R&D and Commercial Progress: Advancing multiple late-stage clinical trials while scaling global commercialization enhances future revenue optionality.
Investors will be watching TGTX’s execution on both its new BRIUMVI regimens and the ramp in ex-U.S. sales for further signs that this rare profitability among mid-cap biotech can be sustained. As with any rapidly evolving growth story, risks remain—but for now, momentum is clearly on TGTX’s side.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI